High materiality7/10
Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity reiterates Buy on BHVN; target $21; price $16.11; Analyst Sumant Kulkarni.
- Canaccord reiterates Buy on BHVN; target $21 (price $16.11).
Key facts
- 01
Target: $21
- 02
Posted price: $16.11
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Sumant Kulkarni
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.